Bio-Rad Laboratories (BIO) Cash & Equivalents (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Cash & Equivalents data on file, last reported at $507.2 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 2.72% year-over-year to $507.2 million in Q1 2026; TTM through Mar 2026 was $507.2 million, a 2.72% decrease from a year earlier, with the FY2025 full-year figure at $529.8 million, up 8.54% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $507.2 million, down from $529.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for BIO reached as high as $802.3 million in Q1 2022 and fell as low as $369.3 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $478.2 million across 5 years, with a median of $457.8 million in 2023.
• Across the five-year window, Cash & Equivalents plunged 42.15% in 2023 and increased 20.88% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $434.2 million in 2022, then slipped by 7.0% to $403.8 million in 2023, then advanced by 20.88% to $488.1 million in 2024, then advanced by 8.54% to $529.8 million in 2025, then fell by 4.27% to $507.2 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $507.2 million in Q1 2026, $529.8 million in Q4 2025, and $395.8 million in Q3 2025.